Our Company

Slider

About ImmunityBio, Inc.

ImmunityBio, Inc. is a late-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancer and infectious disease. The company’s immunotherapy platform is designed to activate both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term “immunological memory.” This novel approach is designed to eliminate the need for high-dose chemotherapy, improve the outcomes of current CAR T-cell therapies, and extend beyond checkpoint inhibitors.
ImmunityBio has established three fundamental platforms to drive long-term immunological memory. These include first-in-class antibody cytokine fusion proteins, synthetic immune modulators, and second-generation vaccine vector platforms.
Fusion Proteins
Activators

Activated
NK & T Cell

Albumin-Bound
Immuno-Modulators

Activated M1
Macrophages

Adenovirus & Yeast
Vaccines

Memory
T Cells

ImmunityBio’s lead cytokine infusion protein, a novel interleukin-15 (IL-15) superagonist complex (Anktiva™), has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC). Other indications currently at registration-stage trials include BCG-unresponsive papillary bladder cancer, first- and second-line lung cancer, triple-negative breast cancer, metastatic pancreatic cancer, recurrent glioblastoma, and soft tissue sarcoma in combination with the company’s synthetic immune modulator (Aldoxorubicin).

ImmunityBio is also developing therapies, including vaccines, for the prevention and treatment of HIV, influenza, and the coronavirus SARS-CoV-2 with its second-generation human adenovirus (hAd5) vaccine platform.

Partnering

The research and development of cell therapy product candidates require an exceptional team of people with scientific and clinical expertise across a range of disciplines. We seek to forge collaborations with leading strategic partners, key researchers, and top medical centers to accelerate the development of our first-in-class product candidates and modalities.

Please email info@immunitybio.com to reach out to our partnering team for further discussion.

ImmunityBio logo
+1 310-883-1300

info@immunitybio.com
9920 Jefferson Blvd. Culver City CA 90232